MRK
NYSE
Pharmaceuticals
$125.45
USD
+$5.25 (+4.37%)
Last close
Market Cap:
$303.70B
Volume:
13.9M
Previous Close
$120.20
Day Range
$121.00 - $125.96
52 Week Range
$76.66 - $125.14
Average Volume (10 Days)
13.2M
P/E Ratio
16.64
Dividend Yield
2.71%
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
CEO
Mr. Robert Davis
Headquaters
Rahway, NEW JERSEY, US
Founded
1941
Employees
75,000
Merck and Moderna presented five-year follow-up data from their phase 2b trial showing that intismeran autogene, a personalized mRNA cancer vaccine combined with KEYTRUDA, reduced the risk of melanoma recurrence or death by 49% compared to KEYTRUDA alone in high-risk patients. The therapy has now advanced to phase 3 trials and demonstrated a manageable safety profile with no serious vaccine-related adverse events.
0
0
Merck reported first-quarter sales of $16.29 billion, surpassing expectations on 12% growth from Keytruda. The company raised its full-year earnings guidance while navigating the 2028 patent expiration for its flagship cancer drug, which accounts for over half of pharmaceutical sales.
0
0
PFE
Pfizer Inc
$23.67
-2.0%